A quantitative clinical comparison of three 99mTechnetium labeled brain imaging radiopharmaceuticals.
In a comparison study of three commonly employed 99mTc brain imaging pharmaceuticals, 16 patients with proven brain lesions had imaging performed with DTPA, glucoheptonate, and pertechnetate over a short interval of time. Lesion detectability was assessed by a data processing system which evaluated average lesion-to-background activity ratios for each patient examination. Statistical analysis of the resultant data demonstrated a significant improvement (20%) in lesion-to-background ratio in favor of one hour delayed DTPA images versus two hour delayed pertechnetate images. Comparison of one hour delayed DTPA images with one hour delayed glucoheptonate images did not reveal a significant difference in lesion-to-background ratio. The authors conclude that both Tc-DTPA and Tc-glucoheptonate are superior alternatives to pertechnetate when employed in the manner described.
D001921:Brain / Q000000981:diagnostic imaging*; D001932:Brain Neoplasms / Q000000981:diagnostic imaging; D006539:Heptoses; D006801:Humans; D004369:Pentetic Acid; D011877:Radionuclide Imaging; D013400:Sugar Acids; D013667:Technetium; D013997:Time Factors
D006539:Heptoses; D013400:Sugar Acids; D013667:Technetium; D004369:Pentetic Acid